Lenvatinib also inhibits STAT5 phosphorylation, reduces Treg differentiation and infiltration, and modulates the tumor immune microenvironment by promoting GZMK+CD8 T cell infiltration and reducing TIM-3 and CTLA-4 expression on Tregs, further enhancing the antitumor response 156. Here, CD8A is linked to neoplasm.